25th Oct 2019 10:37
(Alliance News) - Neuroscience technology firm Cambridge Cognition PLC said Friday it has spotted a potential opportunity, following two pharmaceutical firms signing an agreement to pursue regulatory approval for aducanumab.
On Tuesday, Biogen Inc announced plans to file for the approval of aducanumab, which would be the first therapy to take on clinical decline in early Alzheimer's disease, following "new analysis" of a larger dataset from a phase three clinical trial.
Biogen will be undertaking this in cooperation with Eisai Co Ltd, a Japanese research and development-based pharmaceutical company.
Cambridge Cognition said this agreement offers an opportunity for the company, as its CANTAB assessments are particularly sensitive to the early cognitive decline during Alzheimer's disease.
Biogen indicated it will file for the drug's approval in the US early next year. If approved, it would become the first drug to slow the progression of Alzheimer's disease, however it will also raise the challenge of finding and assessing patients most likely to benefit from such treatment.
Cambridge Cognition said its CANTAB product could support clinicians in making such decisions.
CANTAB delivers an automated memory assessment and depression scale to distinguish older patients who have concerns about their memory from those at increased risk of dementia.
"We were delighted to hear the news of Biogen's re-invigorated Alzheimer's programme, as it holds promise for the millions of people worldwide who are affected by the disease. We are therefore preparing for the approval of disease modifying treatments so that patients and families can benefit from new therapies as soon as possible," said Chief Executive Matthew Stork.
"CANTAB is a medical device that can help clinicians in identifying the right patients for these potential new treatments," Stork added.
Shares in Cambridge Cognition were down 1.4% at 25.16 pence on Friday in London. Biogen's shares closed 2.5% higher on Thursday in New York at USD285.68, remaining flat in pre-market trade.
By Dayo Laniyan; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Cambridge Cog